Perimeter Medical Imaging AI Announces Completion of Two New Commercial Placements of Perimeter S-Series OCT
10 Enero 2023 - 7:30AM
Business Wire
- Completed two follow-on commercial placements of Perimeter
S-Series OCT at the end of 2022
- Doubled the commercial installed base of S-Series OCT during Q4
2022
Perimeter Medical Imaging AI, Inc. (TSX-V: PINK) (OTC: PYNKF)
(FSE: 4PC)(“Perimeter” or the “Company”) – a commercial-stage
medical technology company – today reported two new commercial
installations of its flagship Perimeter S-Series OCT system, which
were completed prior to year-end.
Jeremy Sobotta, Perimeter’s Chief Executive Officer stated, “I
am excited by our considerable progress across the business, and we
enter 2023 with growing momentum. Prior to year-end, we completed
two additional commercial placements of our S-Series OCT
technology, including successfully leveraging our existing presence
within a major national healthcare system, resulting in the third
commercial placement in this network.”
Mr. Sobotta continued, “These two new placements at the end of
2022 were a great way to close a strong fourth quarter in which we
doubled the total commercial installed base of our S-Series
devices. Further, we believe the expansion within our existing
customers’ networks indicates the value these early users are
experiencing. These positive metrics are highly encouraging, and we
remain focused on placing our innovative medical imaging technology
in ORs across the U.S. with the goal of improving patient outcomes
and reducing overall healthcare costs.”
About Perimeter Medical Imaging AI, Inc.
Based in Toronto, Canada and Dallas, Texas, Perimeter Medical
Imaging AI (TSX-V: PINK) (OTC: PYNKF) (FSE: 4PC) is a medical
technology company driven to transform cancer surgery with
ultra-high-resolution, real-time, advanced imaging tools to address
areas of high unmet medical need. Available across the U.S., our
FDA-cleared Perimeter S-Series OCT system provides real-time,
cross-sectional visualization of excised tissues at the cellular
level. The breakthrough-device-designated investigational Perimeter
B-Series OCT with ImgAssist AI represents our next-generation
artificial intelligence technology that is currently being
evaluated in a pivotal clinical trial, with support from a grant of
up to US$7.4 million awarded by the Cancer Prevention and Research
Institute of Texas. The company’s ticker symbol “PINK” is a
reference to the pink ribbons used during Breast Cancer Awareness
Month.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward-Looking Statements
This news release contains statements that constitute
“forward-looking information” within the meaning of applicable
Canadian securities legislation. In this news release, words such
as “may,” “would,” “could,” “will,” “likely,” “believe,” “expect,”
“anticipate,” “intend,” “plan,” “estimate,” and similar words and
the negative form thereof are used to identify forward-looking
statements. Forward-looking information may relate to management’s
future outlook and anticipated events or results and may include
statements or information regarding the future financial position,
business strategy and strategic goals, competitive conditions,
research and development activities, projected costs and capital
expenditures, research and clinical testing outcomes, taxes and
plans and objectives of, or involving, Perimeter. Without
limitation, information regarding the potential benefits of
Perimeter S-Series OCT, Perimeter B-Series OCT, and Perimeter
ImgAssist; Perimeter’s expected marketing and sales activities; and
Perimeter’s business focus are forward-looking information.
Forward-looking statements should not be read as guarantees of
future performance or results, and will not necessarily be accurate
indications of whether, or the times at or by which, any particular
result will be achieved. No assurance can be given that any events
anticipated by the forward-looking information will transpire or
occur. Forward-looking information is based on information
available at the time and/or management’s good-faith belief with
respect to future events and are subject to known or unknown risks,
uncertainties, assumptions, and other unpredictable factors, many
of which are beyond Perimeter’s control. Such forward-looking
statements reflect Perimeter’s current view with respect to future
events, but are inherently subject to significant medical,
scientific, business, economic, competitive, political, and social
uncertainties and contingencies. In making forward-looking
statements, Perimeter may make various material assumptions,
including but not limited to (i) the accuracy of Perimeter’s
financial projections; (ii) obtaining positive results from trials;
(iii) obtaining necessary regulatory approvals; and (iv) general
business, market, and economic conditions. Further risks,
uncertainties and assumptions include, but are not limited to,
those applicable to Perimeter and described in Perimeter’s
Management Discussion and Analysis for the year ended December 31,
2021, which is available on Perimeter’s SEDAR profile at
www.sedar.com, and could cause actual events or results to differ
materially from those projected in any forward-looking statements.
Perimeter does not intend, nor does Perimeter undertake any
obligation, to update or revise any forward-looking information
contained in this news release to reflect subsequent information,
events, or circumstances or otherwise, except if required by
applicable laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230110005417/en/
Jeremy Sobotta Chief Executive Officer Perimeter Medical Imaging
AI, Inc. Toll-free: 888-988-7465 (PINK) Jodi Regts Perimeter
Medical Imaging AI, Inc. Direct: 469-743-1834 Investors:
investors@perimetermed.com Media: media@perimetermed.com
Simplify Exchang (NYSE:PINK)
Gráfica de Acción Histórica
De Mar 2025 a Abr 2025
Simplify Exchang (NYSE:PINK)
Gráfica de Acción Histórica
De Abr 2024 a Abr 2025